However, the high number of cardiac adverse events (up to 13% grade 3–4) observed in the German-Austrian AML Study Group 16–10 [12] in this category of patients when treated with both midostaurin and strong CYP3A4 inhibitors confirms the urgent need of pharmacokinetic studies. The gene discussed is CYP3A4; the disease is acute myeloid leukemia.